Cathy Eng, MD, FACP, FASCO

Vanderbilt-Ingram Cancer Center, MD Anderson Cancer Center
MD Anderson Cancer Center

Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, Co-Director of GI Oncology and the Co-Leader of the Gastrointestinal Cancer Research Program, Director of the new Young Adults Cancers Program, and the Chair, Developmental Research Program for the GI SPORE, at the Vanderbilt-Ingram Cancer Center. She has served on the Scientific Review Committee and remains on the Clinical Trials Shared Resource Oversite Committee. She has focused on the development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients.

Nationally, Dr. Eng serves on ASCO, ECOG, and SWOG. She served on multiple committees for ASCO; ASCO Scientific Program Committee Track Leader for the Gastrointestinal Cancer-Colorectal/Liver Track and served on the Steering Committee 2012-2015. She is the former Chairman of the Scientific Program Committee of the ASCO Gastrointestinal Cancer Symposium from 2012-2013 and Chairman, Steering Committee, GI Cancers Symposium 2016. She was chosen for the ASCO Leadership Development Program and served on the ASCO Government Relations Committee; worked with the ASCO Cancer Prevention Committee on the consensus statement regarding HPV vaccination; served on the ASCO Nausea and Vomiting Guidelines Committee, ASCO Taxonomy Task Force, ASCO Social Media Committee, and is currently on the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee and the ASCO Communications Committee. She serves on the NCI GI Steering Committee, and is now the co-Chair of the NCI GI Steering Committee.

Presentation(s):

• Q&A; Post-Session Audience Survey

  Friday, September 24, 2021
  10:15 AM – 11:00 AM CDT

• Introduction and Pre-Session Audience Survey

  Friday, September 24, 2021
  12:05 PM – 12:10 PM CDT

• Session V: Hepatobiliary Cancers

  Friday, September 24, 2021
  12:05 PM – 3:05 PM CDT

• Debate Discussion

  Friday, September 24, 2021
  12:56 PM – 1:00 PM CDT

• Q&A; Post-Session Audience Survey

  Friday, September 24, 2021
  2:20 PM – 3:05 PM CDT

• Introduction and Pre-Session Audience Survey

  Saturday, September 25, 2021
  9:00 AM – 9:05 AM CDT

• Session VII: Rare Tumors

  Saturday, September 25, 2021
  9:00 AM – 10:50 AM CDT

• Debate Discussion

  Saturday, September 25, 2021
  10:01 AM – 10:05 AM CDT

• Q&A; Post-Session Audience Survey

  Saturday, September 25, 2021
  10:05 AM – 10:50 AM CDT

• Closing Remarks

  Saturday, September 25, 2021
  3:30 PM – 3:35 PM CDT

• Debate Discussion

  Thursday, October 28, 2021
  9:51 AM – 9:55 AM CDT

• Q&A; Post-Session Audience Survey

  Thursday, October 28, 2021
  10:15 AM – 11:00 AM CDT

• Debate: First-Line Treatment in Left-Sided, RAS/BRAF Wild-Type Metastatic Colorectal Cancer: EGFR Inhibitors vs. VEGF Inhibitors: VEGF Inhibitors.

  Thursday, October 28, 2021
  12:38 PM – 12:46 PM CDT

• Debate Discussion

  Thursday, October 28, 2021
  12:46 PM – 12:50 PM CDT

• Debate Discussion

  Thursday, October 28, 2021
  1:06 PM – 1:10 PM CDT

• Debate Discussion

  Thursday, October 28, 2021
  1:46 PM – 1:50 PM CDT

• Q&A; Post-Session Audience Survey

  Thursday, October 28, 2021
  1:50 PM – 2:35 PM CDT

• Early-Onset Colorectal Cancer: A Biologically Distinct Threat?

  Thursday, October 28, 2021
  3:45 PM – 4:05 PM CDT

• Q&A; Post-Session Audience Survey

  Thursday, October 28, 2021
  4:45 PM – 5:30 PM CDT

• Welcome and Introduction; Pre-Session Audience Survey

  Friday, October 29, 2021
  8:00 AM – 8:05 AM CDT

• Session IV: Pancreatic Cancer

  Friday, October 29, 2021
  8:00 AM – 10:00 AM CDT

• Debate Discussion

  Friday, October 29, 2021
  9:11 AM – 9:15 AM CDT

• Q&A; Post-Session Audience Survey

  Friday, October 29, 2021
  9:15 AM – 10:00 AM CDT

• Debate Discussion

  Friday, October 29, 2021
  11:56 AM – 12:00 PM CDT

• Q&A; Post-Session Audience Survey

  Friday, October 29, 2021
  1:20 PM – 2:05 PM CDT

• Introduction and Pre-Session Audience Survey

  Friday, October 29, 2021
  3:10 PM – 3:15 PM CDT

• Session VI: Gastroesophageal Cancer & Other Hot Topics

  Friday, October 29, 2021
  3:10 PM – 5:00 PM CDT

• Debate Discussion

  Friday, October 29, 2021
  3:51 PM – 3:55 PM CDT

• Q&A; Post-Session Audience Survey

  Friday, October 29, 2021
  4:15 PM – 5:00 PM CDT

• Debate Discussion

  Saturday, October 30, 2021
  9:01 AM – 9:05 AM CDT

• Q&A; Post-Session Audience Survey

  Saturday, October 30, 2021
  9:05 AM – 9:50 AM CDT

• Introduction and Pre-Session Audience Survey

  Saturday, October 30, 2021
  10:55 AM – 11:00 AM CDT

• Session VIII: Gastrointestinal Cancer: Emerging Concepts & Therapies

  Saturday, October 30, 2021
  10:55 AM – 12:55 PM CDT

• Q&A; Post-Session Audience Survey

  Saturday, October 30, 2021
  12:10 PM – 12:55 PM CDT

• Case Discussion: Colorectal Cancers

  Saturday, October 30, 2021
  2:25 PM – 2:40 PM CDT

• Case Discussion: Pancreatic Cancer

  Saturday, October 30, 2021
  2:40 PM – 2:55 PM CDT

• Case Discussion: Hepatobiliary Cancers

  Saturday, October 30, 2021
  2:55 PM – 3:10 PM CDT

• Case Discussion: Gastroesophageal Cancers

  Saturday, October 30, 2021
  3:10 PM – 3:25 PM CDT

• Closing Remarks

  Saturday, October 30, 2021
  3:25 PM – 3:30 PM CDT